Our history
Global leader in biosimilar medicines

Alvotech was founded in 2013 by the Chairman, Robert Wessman. His initial strategy was to invest in the development and manufacture of a portfolio of biosimilar monoclonal antibodies and to build a state-of-the-art manufacturing facility in Reykjavik Iceland since then, the investment commitment has increased to more than $600 million and Alvotech has established itself as a key player and up-and-coming powerhouse in the biosimilar space.

7th year

2019

Business

Alvotech completes US$300 million financing deal through a private bond offering

Global

Work begins on Alvotech-CCHN joint venture in China

Product

Alvotech enrolls first patient in clinical phase III study involving biosimilar version of HUMIRA®

Global

Alvotech and Fuji Pharma announce exclusive partnership agreement to commercialize Alvotech’s ustekinumab biosimilar (Stelara®) in Japan

People

Mark Levick appointed CEO of Alvotech

6th year

2018

Iceland

Manufacturing licensure granted by the Icelandic Medicines Agency, in consultation with the Irish Health Products Regulatory Authority for our biopharmaceutical facility in Reykjavik, Iceland

Portfolio

Agreement with Changchun High & New Technology Industries Group Inc (“CCHN”) which will enable Alvotech to develop, manufacture and commercialize its biosimilar portfolio in China

5th year

2017

Business

One biosimilar selection to bring pipeline to seven assets

Business

Acquisition of Glycothera in Hanover, Germany adding further analytical capabilities and expertise

4th year

2016

Product

Next two biosimilars selected to bring pipeline to six assets

Research

Acquisition of development arm of Baliopharm GmbH to further strengthen our R&D platform

Business

Manufacturing facility undergoing first inspection

Business

Inauguration of our Icelandic facility

3rd year

2015

Business

Continuing product development and facility establishment build-up of capacity and staff

2nd year

2014

Products

Development of next two product candidates initiated, bringing pipeline to four biosimilars

Partnership

Partnership agreement with a global pharma company signed

1st year

2013

Business

Founding of Alvotech and start of development for the first two biosimilars

Business

Breaking ground on state-of-the-art, 13,278 squaremeters single use biomanufacturing facility in Reykjavik, Iceland

Business

Strategic investments to increase R&D capabilities